Approximately 2% to 3% of circulating human T cells co-express CD4 and CD8 (CD4+, CD8+) T-cell antigens. These CD4+, CD8+ cells may be immature precursors that function to replenish functional T-cell subsets. We detected a very high level of CD4+, CD8+ cells in the peripheral blood lymphocytes of a healthy white male, ranging from 21% to 36%. The morphology of his peripheral blood lymphocytes was normal, and he has maintained an elevated level of CD4+, CD8+ cells without clinical disease over a 19-month observation period. The CD4+, CD8+ cells did not possess thymocyte membrane antigen (CD6). nor did they have increased Tac (CD25) antigen. His intact, purified blood T cells had a normal proliferative response to phytohemagglutinin and interleukin-2 (IL-2). provided help for B-cell proliferation at control levels and exposure to IL-2 resulted in generation of cytotoxic cells.
However, the purified blood CD4+, CD8+ cells were deficient in these latter functions except for help in B-cell function. Despite defective function, the isolated CD4+, CD8+ cells co-expressed CD2 and CD3. Prolonged in vitro culture of CD4+, CD8+ cells was possible in the presence of recombinant IL-2. The cultured CD4+, CD8+ cells retained the double antigens (CD4 and CD8) throughout a &week period. It is likely these cells are less mature than CD4+, CD8-or CD4-, CD8+ T cells as the CD4+, CD8+ have less in vitro function than the former cells, but it is not yet clear if they mature into either CD4+, CD8-, or CD4-, CD8+ cells. Finally, the presence of an expanded, hypofunctioning CD4+, CD8+ cell population in a normal adult male is apparently compatible with excellent clinical health. 0 1990 by The American Society of Hematology.
tion and, over the 14-month observation period, remains healthy. There were no obvious physical abnormalities on examination, and he denied any drug or chemical exposures. His initial complete blood was within normal limits: hemoglobin of 14.6 gm/dL total white blood cell (WBC) count of 6.0 x lO'/pL, and a platelet count of 258 x lO'/pL. His WBC differential was 48% neutrophils, 5% monocytes, and 47% lymphocytes. On repeated observations, the latter cells have consistently been morphologically normal. These hematologic parameters have remained stable over the observation time of 19 months.
Venous blood was drawn into a syringe containing heparin and subjected to Ficoll-Hypaque centrifugation. The interface layer was harvested, and monocytes were removed by adherence to plastic flasks for 1 hour at 37OC. The nonadherent lymphocytes (peripheral blood lymphocytes; PBL) were removed and allowed to rosette with 2-aminoisoethyl isothiouronium bromide (AET)-treated sheep red blood cells (SRBC) for 30 minutes at 4OC. The rosetted lymphocytes were again subjected to Ficoll-Hypaque centrifugation. The pelleted cells were harvested (SRBC rosette positive T cells), and the SRBC were lysed by brief exposure to distilled water. The purity of this SRBC positive T-cell fraction (designated intact T) was greater than 95%, as determined by either rechallenge with AET-treated SRBC or monoclonal antibody reactivity for CD2 (see below).
Flow cytometry phenotyping and sorting of lymphocytes. Conjugated monoclonal antibodies to detect CD4 and CD8 antigen include anti-Leu-3 (CD4) phycoerythrin (PE) and anti-Leu-2 (CD8) fluorescein isothiocyanate (FITC) (Becton-Dickinson, Mountainview, CA). Monoclonal anti-thymocyte antigen (CD6), anti-Leu-11 (CD16), and anti-Leu-12 (CD19) were also from BectonDickinson. The monoclonal antibody anti-TAC (CD25; reactive with the p55 chain of the interleukin-2 receptor) was a gift of Dr T. Waldmann, National Institutes of Health, Bethesda, MD. Goat anti-mouse [F(ab'),] conjugated to FITC was from Cappel Laboratories (West Chester, PA). FITC-or PE-conjugated isotype controls for the various monoclonal antibodies were also purchased from Becton-Dickinson. Monoclonal antibody to the cu/b heterodimer of the T-cell receptor was TCRI, a/@ WT31, biotin-conjugated and purchased from Becton-Dickinson. Monoclonal antibody to the delta chain of the y/6 T-cell receptor was TCRG1, biotin-conjugated and purchased from T-cell Sciences, Cambridge, MA.
Reactivity of PBL or T cells for individual monoclonal antibodies (MoAbs) was determined by incubating 1 x lo6 cells in 50 pL of phosphate-buffered saline, pH 7.2 (PBS) containing 0.1% NaN, for Lymphocyte purification. For dual staining, cells at 1 x 106/mL were incubated for 30 minutes on ice with FITC-conjugated anti-Leu-3 (CD4) and PEconjugated anti-Leu-2 (CD8). After incubation, the cells were washed three times and then either analyzed immediately by flow cytometry or fixed in 1% pformaldehyde in 0.15 mL PBS, and stored until analysis. Samples analyzed fresh or after fixation have essentially the same MoAb reactivity.
Samples were analyzed by multiparameter flow cytometry using a FACS 440 system with an argon (488 nm) and a rhodamine 620 nm dye laser. Data analysis was done using a Consort 40 system (Becton-Dickinson). FITC-or PE-conjugated MoAbs of different isotypes, unreactive with human T cells, were used to control for nonspecific fluorescence.
Cells reactive for both CD4 and CD8 MoAbs, ie, CD4+, CD8+ cells, via the methodology described above, were sorted at 4,000 cells per second after appropriate gating using the FACS 440 system.
Aliquots of PBL, T, or purified CD4+, CD8+ cells were added at 1 x lo5 cells per well (96-well microtiter plates) in a total volume of 20 pL RPMI (GIBCO, Grand Island, NY) with 10% fetal calf serum (FCS). To each well was added either concanavalin A (ConA, 0.1 to 10 pg/mL; Calbiochem, San Diego, CA), phytohemagglutinin (PHA, 1 to 10 pg/mL; Burroughs Wellcome Co, Research Triangle Park, NC), or recombinant interleukin-2 (rIL-2) (10, 100, or 1,000 units/mL; Cetus Corp, San Francisco, CA). Cells were cultured for three days at 37% in 5% CO,. Tritiated thymidine (,H-TdR, 0.5 pCi; New England Nuclear, Boston, MA) was then added to each well, and an additional 6-hour incubation was carried out. The cells were harvested on a MASH I1 apparatus, and 'H-TdR incorporation was measured in a Packard scintillation counter as mean cpm of triplicate cultures.
T-cell help for B-cell proliferation or immunoglobulin synthesis. To determine T-cell assistance for both pokeweed mitogen (PWM)-induced B-cell proliferation and immunoglobulin (Ig) synthesis, we performed the following assays. Irradiated T cells or irradiated purified CD4+, CD8+ T cells (see above) from our subject were added at 1 x 106/mL to autologous purified B cells (1 x lo6 cells/mL). The cell suspensions were cultured in 24-well microtiter plates for 3 to 5 days in RPMI medium with 10% FCS at 37OC in 5% CO,. At initiation of culture, triplicate wells received either PWM (10 pg/mL) or an equivalent volume of RPMI medium.
To measure B-cell proliferation, 0.5 pCi of 'H-TdR was added to the B-and T-cell suspensions after 72 hours of culture, and incubation was continued for an additional 12 hours. The amount of B cell 'H-TdR incorporation was assayed as described above for T-cell proliferation. To assay for B-cell Ig secretion, we used an enzyme-linked immunosorbent assay (ELISA), specific for IgG, IgM, and IgA, on culture supernatants harvested from the B-and T-cell suspensions after 5 days of in vitro culture. The ELISA was performed as described previ~usly.~ Controls for both proliferation and Ig synthesis consisted of culturing purified T cells from age and sex matched normal donors and B cells alone with and without PWM.
To determine if the CD4+, CD8+ cells contain detectable natural cytotoxicity/killer (NK) function or if exposure to recombinant interleukin-2 (rIL-2) would generate detectable NK activity, we used the following assay. NK function was determined for total T or CD4+, CD8+ (effector cells) incubated for 16 hours with medium alone or in the presence of rIL-2. The NK-sensitive cell line K562 (a human myeloid leukemia Lymphocyte activation.
Natural cytotoxic assay.
cell line) was used as the target cell. K562 cells were grown in RPMI with 10% FCS, resuspended to 1 x 106/mL, and labeled for 1 to 2 hours with 100 to 200 pCi of 5'Cr (New England Nuclear). The target cells were washed three times and adjusted to lo5 cells/mL in RPMI. Then 0.1 mL of threefold serial dilutions of effector cells and 0.1 mL target cells were admixed in round-bottomed microtiter wells (Linbro, Hamden, CT). All experiments were done in triplicate. Triplicate wells with target cells in medium alone and target cells in 1% Triton-X100 were incubated to determine spontaneous and total release, respectively. The plates were centrifuged for 5 minutes at lOOg and incubated for 16 hours at 37OC in a humidified CO, atmosphere. Then 0.1 mL aliquots of supernatant were removed and counted in a gamma counter. The percentage of 51Cr release from target cells was calculated by the formula: (experimental release-spontaneous release)/(total release-spontaneous release).
Spontaneous release was always less than 5% of total counts/hour. Variance among triplicates was less than 10%. Data is presented as lytic units per lo6 cells, where a lytic unit is arbitrarily defined as number of cells cytotoxic for 15% of target cells.
We attempted to grow the subject's CD4+, CD8 + cells in vitro. This was accomplished by sorting, via flow cytometry (see above), dual stained CD4+, CD8+ cells from our subject's blood lymphocytes into microtiter wells. Per well, 1 x lo4 cells were grown with 100 units of rIL-2 (Cetus Corp) in RPMI with 10% FCS. Cells were re-fed with fresh medium and rIL-2 every 2 to 3 days. Weekly estimations of viability (by Trypan blue exclusion), cell numbers, and surface phenotype were also done.
To perform three-color analysis, we used a technique previously described.6 In brief, lymphoid cells were reacted with FITC-conjugated, PE-conjugated, and biotin-conjugated antibodies for 20 minutes (on ice) and were then washed. Streptavidin allophycocyanin (APC) conjugate was added, and cells were incubated for an additional 20 minutes and fixed in 1% paraformaldehyde or analyzed immediately by FACS 440. We used the optical configuration and filter combination for three-color immunofluorescence using FITC, PE, and APC6 A minimum of 20,000 events for each sample were collected in list mode on a Consort 40 Data Management System (Becton-Dickinson). Our fluorescence control included nonimmune MoAbs of appropriate isotype conjugated to FITC, PE, or cells labeled with streptavidin-APC. T-cell receptor gene rearrangement analysis was done on high-molecular-weight DNA extracted from peripheral blood mononuclear cells and purified CD4 + , CD8 + cells. The DNA was digested with EcoRI or HindIII, sizefractionated on 0.8% agarose gels, and then transferred to nitrocellulose paper by the Southern technique. The cDNA probe reactive for the human beta constant genes (provided by Dr T.W. Mak, Toronto, Ontario) was labeled with "P by randomizing. After hybridization, the blots were washed at the appropriate stringency, and autoradiography was done.
In vitro culture of CD4+, CD8+ cells.
Three-color analysis.
Southern blot method.

RESULTS
Lymphocyte surface marker analysis. T h e CD4+, CD8 + T cells were detected in our subject by dual-staining of PBL on flow cytometry (Fig 1) . Purified Detailed examination of his peripheral blood lymphocytes through microscopic study of Wright-Giemsa-stained peripheral blood or Ficoll-Hypaque preparations of PBL or T cells has not revealed obvious morphologic abnormalities.
The initial MoAb analysis of his PBL demonstrated 9.1% B cells (CD19+), 78% T cells (CD2+), 25% T helper phenotype (CD4+), 27% T suppresssor phenotype (CD8 +), 26% CD4+, CD8+ phenotype, and 6.5% NK phenotype (CD16+). This cell surface phenotype has remained essentially the same during our 19-month study.
Purified peripheral blood T lymphocytes and CD4+, CD8+ cells were negative for the presence of either TAC antigen (CD25, IL-2 receptor) or thymocyte antigens (CD6) by cell surface marker analysis. In addition, these cells were negative for terminal deoxynucleotidyl transferase (TdT) activity.' Because his CD4+, CD8+ T cells were poorly responsive to phytohemagglutinin (PHA) and IL-2 (see below), we also determined the presence of CD2 and CD3 membrane antigens. These two antigens are known to be important in the human T-cell proliferative response.s39 Three-color staining of his CD4+, CD8+ T cells demonstrated that his CD4+, CD8+ T cells expressed both CD2 and CD3. In addition, the fluorescence intensity for CD2 or CD3 was equivalent to that seen in the CD4+, CD8-or CD4-, CD8+ T cells (data not shown). Three-color analysis of the CD4+, CD8 + T cells also showed that these cells were uniformly reactive for the a/S T-cell receptor (data not shown).
To assess the possible clonal nature of the patient's isolated T cells, we performed Southern blot analysis on isolated DNA from total T and CD4+, CD8+ cells. DNA was probed using the cDNA for beta chain of the T-cell receptor.
No clonal rearranged bands were detected on autoradiograSince it is not known if peripheral blood CD4+, CD8+ cells are capable of differentiating into either CD4+, CD8-or CD4-, CD8+ cells, we attempted to culture these CD4+, CD8+ cells with rIL-2. Purified CD4+, CD8 + cells (sorted by flow cytometry) were maintained in cell culture for 8 weeks. The presence of rIL-2 was critical, as control cultures of CD4+, CD8+ cells did not grow or remain viable for longer than 5 days in RPMI medium alone (data not shown). In the presence of rIL-2 (100 units/mL), we were able to demonstrate both excellent viability (greater than 90%) over the 6-week culture period and continued exclusive expression of the CD4+, CD8 + phenotype on dual-staining (Fig 2) .
Functional analysis of the subject's CD4+, CD8+ T cells. A major focus of our in vitro studies was to delineate the functional capacity of our subject's CD4+, CD8 + T cell cohort. This represented a unique opportunity to assay easily obtainable, nonleukemic peripheral blood CD4+, CD8 + T cells and to compare them to the subject's and to age and sex-matched normal total T (SRBC positive) cell populations. The latter control was used on occcasion to determine if the subject's total T-cell population responded or performed optimally in the in vitro assays, described below.
Initially, we assayed the lymphocyte proliferative response of CD4+, CD8+ T and total T cells to PHA, ConA and rIL-2 ( Table 1 ). The subject's CD4+, CD8+ T cells were obviously defective in responding to the two mitogens (PHA, ConA) or rIL-2 (Table 1 ). In contrast, the total T-cell phy.
In vitro culture of CD4+, CD8+ blood cells. population from our subject and an age, sex-matched control had cell proliferation that followed a dose response curve. Despite the use of several different concentrations of mitogen and rIL-2, we did not detect thymidine incorporation above background in CD4+, CD8+ T cells, except for rIL-2 at 100 and 1,000 units/mL (Table 1) . We then assayed for the ability of these CD4+, CD8+ T cells to mediate help in a PWM assay for B-cell proliferation or Ig synthesis (Tables 2 and 3 , respectively). In contrast to the marked inability of the CD4+, CD8+ cells to proliferate, they appear to be very efficient at mediating help for autologous B cells. They were at least as efficient as his total T cells in the induction of B-cell proliferation (Table 2) and Ig synthesis (Table 3 ). In the latter assay, we titrated his total T and CD4+, CD8+ cells from 1 x 104/mL to 1 x 106/mL in an attempt to detect functional differences (Table  3) . At all cell concentrations, similar results were obtained with both T cell groups. Finally, both his CD4+, CD8+ and total T cells were as efficient in these proliferative and Ig assays as total T cells from an age and sex-matched donor run concurrently (data not shown).
We assessed the ability of his PBL and CD4+, CD8+ cells to perform as NK cells. Figure 3 is a representative experiment for NK function of his total T and purified CD4+, CD8+ cells. His purified CD4+, CD8+ cells exhibited little or no NK activity. In contrast, his total T had clearly demonstrable NK function (Fig 3) . Both total T and purified CD4+, CD8+ cells were incubated with rIL-2 for 16 hours before the NK assay in an attempt to demonstrate enhancement of NK activity. Figure 3 demonstrates that his PBL had a brisk increase in NK function for all three rIL-2 concentrations (10, 100, or 1,000 units/mL), while the CD4+, CD8+ cells had only a slight increment in this function.
DISCUSSION
We have detected the presence of a large number of CD4+, CD8+ T cells in the peripheral blood of a healthy adult. Previous investigations have documented that normal individuals have much smaller numbers (around 3%) of CD4 +, CD8 + T celk3x4 We found that the isolated blood CD4+, CD8+ T cells were deficient for proliferative response to mitogens or rIL-2, while they were able to provide help for B-cell proliferation or Ig synthesis/secretion. Therefore, function of these blood CD4+, CD8 + T cells resembles, in part, the CD4+, CD8+ T cells normally resident in the thymus."-13 The major issues of this study are the clinical significance of large numbers of circulating CD4 +, CD8 + cells in their role in host immune response and their potential relationship to the more mature and usual residents of blood T cells, the CD4+, CD8 -, and CD4-, CD8 + cells. CD4+, CD8+ T cells normally circulate in peripheral blood of healthy adult^.^.^ However, the percent of CD4+, CD8 + T cells is usually very low, with a range of 2% to 6%.'
The majority of normal blood T lymphocytes possess CD4 or CD8 membrane antigen. Elevated levels of blood CD4+, CD8 + T cells have been reported in patients with Behcet's syndrome4 and in patients with lymphoblastic l y m p h~m a . '~* '~ Our subject's CD4+, CD8+ T cells were not a clonal population. This was based on the Southern blot analysis that did not detect a clonal band of rearranged DNA. In addition, these cells were TdT negative, and their 'morphology was normal. To our knowledge, this is the first description of a healthy adult with a major proportion of blood T lymphocytes co-expressing CD4+ and CD8+. While we have observed this subject for 19 months, he has no obvious clinical disorder. The presence of large numbers of these partial immuno-incompetent T cells have not perturbed his resistance to disease or resulted in obvious immunodeficiency. This is not surprising since immune function studies of his total T cells were at normal levels. Since we detected these cells on a routine survey of blood donors, it is possible that a more extensive immunophenotyping survey of healthy adults may reveal that a proportion of healthy individuals also possess increased numbers of CD4+, CD8 + T cells.
There is very little data regarding the function of circulating CD4+, CD8+ Tcells in humans. The CD4+, CD8+ T cells studied here lacked the presence of thymocyte antigen (CD6) and are thus likely to be more differentiated than the CD4+, CD8+ T cells found in the thymus. In addition, they expressed CD2, CD3 and the mature T-cell receptor CY/& CD2 and CD3 antigens are found on mature T cells and are critical for T-cell proliferation in response to mitogen or It is clear, however, that the CD4+, CD8 + T cells are not fully immunocompetent. They had absent to poor proliferative responses to mitogen and recombinant IL-2. In addition, they were not able to generate cytotoxicity for K562 cells with IL-2. These latter findings are consistent with a recent report demonstrating that cortical thymocytes have deficient expression for the p55 chain of the IL-2 receptor." However, they were very efficient at promoting normal B-cell proliferation and Ig synthesis/secretion. Thus, they appear to be partially immunocompetent. These findings suggest that these blood T cells could be precursor cells capable of differentiation into more mature T cells, perhaps similar to the normal maturation steps that occur in the thymus. However, to prove this would require demonstration that a pure population of CD4+, CD8+ T cells alters membrane phenotype and acquires the immune function repertoire of a CD4+, CD8-or CD4-, CD8+ T cell, respectively. Since the IL-2 propagated CD4+, CD8+ T cells were not capable of selective CD4 or CD8 antigen loss, it is less likely that these CD4+, CD8+ T cells are precursor cells. However, it is possible that these cells may be capable of functional maturation under in vivo conditions. Further in vitro study of these CD4+, CD8+ T cells with the aim of determining their potential to generate mature CD4+ or CD8+ T cells would be instructive. This is important because the number and ratio of T cells bearing either CD4 or CD8 play a critical role in regulation of several different immune functions. 
